This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Synopsis: Lupin Limited has entered a $50 million licensing and supply agreement with Zentiva to commercialize its biosimilar Certolizumab Pegol across global markets. Lupin has entered into a License and Supply Agreement with Zentiva, k.s., While Zentiva will lead sales in Europe and CIS, Lupin will manage development and supply.
It is the world’s largest supplier of generic medicine, in terms of volume with a 20% market share. Following global demand, Cipla has deepened its portfolio for the US markets with continued traction in the respiratory franchise and expansion of its peptide portfolio with increased market share in the Company’s first Lanreotide injection.
The reaction to the online portfolio management solutions (aka the “robos”) generated the same kind of existential chill down the spine that the newfangled software thing did back in the day; people were once again fearful that a computer would replace them. Real advisors didn’t need that fancy stuff.
She has a fascinating career, starting a PLS working away up as an analyst and eventually, head of outcome-based strategies for Morningstar, eventually rising from that position and portfolio manager to Chief Investment Officer. Let me give you some background on Morningstar Managed Portfolios. I saw how personal money is.
Some investors go for high EPS stocks in order to decrease the underlying volatility of their portfolio. Operating Profit Margin 20.20% Page Industries was established in 1994 as a licensed manufacturer, distributor, and marketer of Jockey International’s products in India. 42,500 EPS ₹613 Stock P/E 62.1 RoCE 67.2% RoCE 38.4%
These divisions have been arranged geographically and the company has a different product portfolio across these divisions. Sun Pharma in-licensed and commercialised an anti-acne product in the US market. We’ll read more about this in the next section of our fundamental analysis of Sun Pharma. making it a leader in the chronic segment.
And by looking at that information and contrasting that with, you know, an independently formulated view that you may have, if there’s an opportunity that arises between the two to play some sort of kind of arbitrage and probabilities in your, in your portfolio construction, that’s the goal of the style of investing we do.
I do believe it should be different regulated differently from portfolio management, which is the typical definition of the registered investment advisor, but that it shouldn’t be the CFP Board that is controlling the regulatory environment for financial planners. Grillo: Next question. Well, we’ve kind of covered this already.
But the doctors that I have spoken to in emergency medicine say that’s absolutely not the case. MORGENSON: This is a $64 trillion question, Barry, and I would love for you to ask every State Attorney General, for instance, why haven’t you gone after for-profit medicine? We’re going to help you make more money.
We organize all of the trending information in your field so you don't have to. Join 36,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content